老年糖尿病口服降糖药物新进展

doi:10.3969/j.issn.1003-9198.2022.10.004

摘要/Abstract

中图分类号:

R587.1

叶德梅, 张俊, 殷汉, 李玲. 老年糖尿病口服降糖药物新进展[J]. 实用老年医学, 2022, 36(10): 986-990.

[1] 国家统计局,国务院第七次全国人口普查领导小组办公室. 第七次全国人口普查公报^[1](第五号)[N]. 中国信息报, 2021-05-12(2)[2022-07-10] .
[2] LI Y, TENG D, SHI X, et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study[J]. BMJ, 2020, 369: m997.
[3] SKYLER J S, BERGENSTAL R, BONOW R O, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association[J]. J Am Coll Cardiol, 2009, 53(3): 298-304.
[4] American Diabetes Association Professional Practice Committee. Standards of Medical Care in Diabetes-2022[J]. Diabetes Care, 2022, 45(Suppl 1): S1-S264.
[5] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华内分泌代谢杂志, 2021, 37(4):311-398..
[6] YANG S H, DOU K F, SONG W J. Prevalence of diabetes among men and women in China[J]. N Engl J Med, 2010, 362(25): 2425-2426.
[7] WANG L M, PENG W, ZHAO Z P, et al. Prevalence and treatment of diabetes in China, 2013-2018[J]. JAMA, 2021, 326(24): 2498-2506.
[8] 中国老年2型糖尿病防治临床指南编写组, 中国老年医学学会老年内分泌代谢分会, 中国老年保健医学研究会老年内分泌与代谢分会, 等. 中国老年2型糖尿病防治临床指南(2022年版)[J]. 中华内科杂志, 2022, 61(1):12-50.
[9] 中国老年保健医学研究会老年内分泌与代谢病分会, 中国毒理学会临床毒理专业委员会.老年人多重用药安全管理专家共识[J]. 中国糖尿病杂志, 2018, 26(9):705-717.
[10] 国家老年医学中心, 中华医学会老年医学分会, 中国老年保健协会糖尿病专业委员会.中国老年糖尿病诊疗指南(2021年版)[J]. 中华糖尿病杂志, 2021, 13(1):14-46.
[11] ZILOV A V, ABDELAZIZ S I, ALSHAMMARY A, et al. Mechanisms of action of metformin with special reference to cardiovascular protection[J]. Diabetes Metab Res Rev, 2019, 35(7): e3173.
[12] PALMA F R, RATTI B A, PAVIANI V, et al. AMPK-deficiency forces metformin-challenged cancer cells to switch from carbohydrate metabolism to ketogenesis to support energy metabolism[J]. Oncogene, 2021, 40(36): 5455-5467.
[13] ESPOSITO K, CHIODINI P, BELLASTELLA G, et al. Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients[J]. Diabetes Obes Metab, 2012, 14(3): 228-233.
[14] WONG C W, LEUNG C S, LEUNG C P, et al. Association of metformin use with vitamin B(12) deficiency in the institutionalized elderly[J]. Arch Gerontol Geriatr, 2018, 79: 57-62.
[15] GU Y, WANG X, LI J, et al. Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment[J]. Nat Commun, 2017, 8(1): 1785.
[16] MORREALE A P, JANETZKY K. Probable interaction of warfarin and acarbose[J]. Am J Health Syst Pharm, 1997, 54(13): 1551-1552.
[17] DASH R P, BABU R J, SRINIVAS N R. Reappraisal and perspectives of clinical drug-drug interaction potential of α-glucosidase inhibitors such as acarbose, voglibose and miglitol in the treatment of type 2 diabetes mellitus[J]. Xenobiotica, 2018, 48(1): 89-108.
[18] CAMPBELL I W, MARIZ S. Beta-cell preservation with thiazolidinediones[J]. Diabetes Res Clin Pract, 2007, 76(2): 163-176.
[19] MUSSO G, CASSADER M, PASCHETTA E, et al. Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis[J]. JAMA Intern Med, 2017, 177(5): 633-640.
[20] SHAIENKO Z O, BOBYREVA L Y. Combination of metformin and pioglitazone and its effect in treatment of comorbid pathology[J]. Wiad Lek, 2018, 71(2 pt 2): 278-280.
[21] LIU J, WANG L N. Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in people with stroke or transient ischaemic attack[J]. Cochrane Database Syst Rev, 2017, 12(12): Cd010693.
[22] 母义明,杨文英,朱大龙,等.磺脲类药物临床应用专家共识(2016年版)[J]. 药品评价,2017,14(1):5-54.
[23] MARRE M, SHAW J, BRÄNDLE M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU)[J]. Diabet Med, 2009, 26(3): 268-278.
[24] STROJEK K, YOON K H, HRUBA V, et al. Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebo-controlled trial[J]. Diabetes Ther, 2014, 5(1): 267-283.
[25] HOLMAN R R. Long-term efficacy of sulfonylureas: a United Kingdom Prospective Diabetes Study perspective[J]. Metabolism, 2006, 55(5 Suppl 1): S2-S5.
[26] KAHN S E, HAFFNER S M, HEISE M A, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy[J]. N Engl J Med, 2006, 355(23): 2427-2443.
[27] 刘晓丹, 李焱. 格列奈类药物的疗效与安全性综合评价[J]. 药品评价, 2015, 12(13):16-20.
[28] SCHWEIZER A, DEJAGER S, FOLEY J E, et al. Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population[J]. Diabetes Obes Metab, 2010, 12(6): 485-494.
[29] SCIRICA B M, BHATT D L, BRAUNWALD E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus[J]. N Engl J Med, 2013, 369(14): 1317-1326.
[30] 纪立农, 郭立新, 郭晓蕙, 等. 钠-葡萄糖共转运蛋白2(SGLT2)抑制剂临床合理应用中国专家建议[J]. 中国糖尿病杂志, 2016, 24(10):865-870.
[31] PERKOVIC V, JARDINE M J, NEAL B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy[J]. N Engl J Med, 2019, 380(24): 2295-2306.
[32] HEERSPINK H J L, STEFÁNSSON B V, CORREA-ROTTER R, et al. Dapagliflozin in patients with chronic kidney disease[J]. N Engl J Med, 2020, 383(15): 1436-1446.
[33] PARVING H H, LAMBERS-HEERSPINK H, DE ZEEUW D. Empagliflozin and progression of kidney disease in type 2 diabetes[J]. N Engl J Med, 2016, 375(18): 1800-1801.
[34] GUTHRIE R. Canagliflozin and cardiovascular and renal events in type 2 diabetes[J]. Postgrad Med, 2018, 130(2): 149-153.
[35] CAHN A, MOSENZON O, WIVIOTT S D, et al. Efficacy and safety of Dapagliflozin in the elderly: analysis from the DECLARE-TIMI 58 study[J]. Diabetes Care, 2020, 43(2): 468-475.
[36] MONTEIRO P, BERGENSTAL R M, TOURAL E, et al. Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME© trial[J]. Age Ageing, 2019, 48(6): 859-866.
[37] 徐春,阎德文.成人2型糖尿病患者口服降糖药物三联优化方案(二甲双胍+二肽基肽酶4抑制剂+钠-葡萄糖共转运蛋白2抑制剂)中国专家共识[J]. 中国糖尿病杂志, 2021, 29(8):561-570.
[38] 邹大进,张征,纪立农.缓解2型糖尿病中国专家共识[J].中国糖尿病杂志, 2021, 29(9):641-652.

老年糖尿病口服降糖药物新进展

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

Metrics

推荐阅读 10

[1]	张星星, 张海洋, 何小菁, 鲁翔. 不同肥胖指标与老年人糖尿病患病风险的调查研究[J]. 实用老年医学, 2024, 38(9): 940-943.
[2]	赵玉玲, 黄婧, 叶文春. 血清γ-氨基丁酸、胰岛素样生长因子-1对老年糖尿病前期病人心血管事件风险的交互作用分析[J]. 实用老年医学, 2024, 38(8): 816-820.
[3]	梁杉杉, 梁欢, 杨珊, 刘建凤. 老年T2DM病人肌少症发生与颈动脉粥样硬化的相关性研究[J]. 实用老年医学, 2024, 38(8): 826-830.
[4]	时雯, 朱平, 周洁, 颜婷, 黄玉杰, 严妍. 胰激肽原酶治疗老年2型糖尿病轻度认知功能障碍的疗效观察[J]. 实用老年医学, 2024, 38(6): 587-591.
[5]	郭淳, 易梦廷, 宗前兴, 周怡, 巫海娣, 莫永珍. 老年2型糖尿病病人6个月内低血糖风险预测模型的构建:一项纵向研究[J]. 实用老年医学, 2024, 38(6): 592-597.
[6]	包海童, 谈萍, 俞沛文, 刘娟, 丁国宪, 佟蔷薇, 王晓东. 基于老年综合评估的2型糖尿病病人衰弱影响因素分析[J]. 实用老年医学, 2022, 36(12): 1264-1268.
[7]	陈明珠, 许勤, 蔡英华. 老年糖尿病合并衰弱病人自我感受负担的现状及影响因素分析[J]. 实用老年医学, 2022, 36(12): 1269-1272.
[8]	祖丽胡玛尔·阿布都艾尼, 刘超. 老年糖尿病的流行病学特点[J]. 实用老年医学, 2022, 36(10): 973-977.
[9]	唐伟, 张子成. 老年糖尿病血糖监测技术新进展[J]. 实用老年医学, 2022, 36(10): 978-982.
[10]	徐千越, 胡云. 注射类降糖药物在老年糖尿病病人中的使用新进展[J]. 实用老年医学, 2022, 36(10): 983-985.
[11]	李盖, 王雷, 孙新娟, 王天元, 陈金安. 老年2型糖尿病并发症的治疗新进展[J]. 实用老年医学, 2022, 36(10): 991-995.
[12]	俞匀, 唐伟, 娄青林. 不同发病年龄新诊断2型糖尿病病人临床特点分析[J]. 实用老年医学, 2022, 36(10): 1015-1018.
[13]	姚铸玲, 王志勇, 熊亚晴, 徐斐. 南京市老年人群高血压合并糖尿病的流行特征[J]. 实用老年医学, 2022, 36(8): 796-800.
[14]	包宇航, 郑仁东. 糖代谢与睾酮关系的研究进展[J]. 实用老年医学, 2022, 36(8): 850-853.
[15]	仰孝群, 欧阳晓俊. 糖尿病与衰弱相关研究进展[J]. 实用老年医学, 2022, 36(7): 655-659.